Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Superficial bladder cancer

R R Hall1

  • 1Freeman Hospital, High Heaton, Newcastle upon Tyne.

BMJ (Clinical Research Ed.)
|April 2, 1994
PubMed
Summary
This summary is machine-generated.

Bladder cancer is strongly linked to industrial revolution exposures and smoking. Despite identifying carcinogens like beta naphthylamine, many cases remain unproven, highlighting ongoing industrial risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.

The Journal of urology·2001
Same author

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·1999
Same author

Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.

European urology·1999
Same author

Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up.

BJU international·1999
Same author

Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.

The Prostate·1999
Same journal

Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial.

BMJ (Clinical research ed.)·2026
Same journal

Venous thromboembolism after mechanical restraint in psychiatric hospitals: population based cohort and self-controlled case series study.

BMJ (Clinical research ed.)·2026
See all related articles

Area of Science:

  • Environmental Health
  • Occupational Medicine
  • Toxicology

Background:

  • Bladder cancer is a significant public health concern, with industrialization and smoking identified as primary drivers.
  • While specific chemical carcinogens (e.g., beta naphthylamine, benzidine) are known, direct exposure can only be proven in a minority of affected individuals.
  • Many industrial chemicals' carcinogenic potential remains unknown, posing a continuous risk in manufacturing settings.

Purpose of the Study:

  • To underscore the link between industrial activities and bladder cancer.
  • To highlight the challenges in attributing bladder cancer to specific occupational exposures.
  • To emphasize the need for continued vigilance regarding industrial carcinogens.

Main Methods:

  • Review of historical and current industrial practices.

Related Experiment Videos

  • Analysis of known chemical bladder carcinogens and their industrial use.
  • Examination of occupational disease claims related to bladder cancer.

    • Main Results:

    • A significant proportion of bladder cancer cases are suspected to originate from industrial exposures, though direct proof is often lacking.
    • Limited success in obtaining industrial disease benefits for bladder cancer patients, indicating diagnostic and legal challenges.
    • Continued use of identified carcinogens in British industry post-identification and a broad spectrum of at-risk industries.

    Conclusions:

    • Industrial revolution and associated smoking are major contributors to bladder cancer.
    • There is a critical need to address the persistent use of known carcinogens and the unknown risks of novel industrial materials.
    • Further research and regulatory action are required to mitigate occupational bladder cancer risks.